Table 7 Data at randomization for simulation 1B
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Single agent | Combination | ASD | |
|---|---|---|---|
n = 100 | n = 100 | ||
Age (years) | 63.8 (±5.0) | 64.3 (±5.5) | 0.1 |
Stage 4 | |||
No | 1 (1.0%) | 0 (0.0%) | 0.14 |
Yes | 99 (99.0%) | 100 (100.0%) | 0.14 |
Site | |||
Visceral | 42 (42.0%) | 46 (46.0%) | 0.08 |
Bone only | 18 (18.0%) | 15 (15.0%) | 0.08 |
Other | 40 (40.0%) | 39 (39.0%) | 0.02 |
Previous treatment | |||
None | 55 (55.0%) | 44 (44.0%) | 0.22 |
Chemo only | 18 (18.0%) | 18 (18.0%) | 0 |
Hormonal only | 19 (19.0%) | 24 (24.0%) | 0.12 |
Chemo + hormonal | 8 (8.0%) | 14 (14.0%) | 0.19 |
ECOG score | |||
0 | 46 (46.0%) | 44 (44.0%) | 0.04 |
1 | 54 (54.0%) | 56 (56.0%) | 0.04 |
Disease free >12 months adjuvant to recurrence | |||
No | 73 (73.0%) | 71 (71.0%) | 0.04 |
Yes | 27 (27.0%) | 29 (29.0%) | 0.04 |